Russell Investments Group’s Zevra Therapeutics ZVRA Stock Holding History

Russell Investments Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$235K	Buy	16,395 +11,284	+221%	+$125K	﹤0.01%	3119
2026 Q1	$47.6K	Sell	5,111 -117	-2%	-$1.05K	﹤0.01%	3348
2025 Q4	$46.8K	Sell	5,228 -1,146	-18%	-$10.8K	﹤0.01%	3325
2025 Q3	$60.6K	Buy	6,374 +4,475	+236%	+$44.9K	﹤0.01%	3202
2025 Q2	$16.7K	Buy	1,899 +1,790	+1,642%	+$14.5K	﹤0.01%	3229
2025 Q1	$816	Sell	109 -67	-38%	-$532	﹤0.01%	3614
2024 Q4	$1.47K	Buy	+176	New	+$1.5K	﹤0.01%	3489
2022 Q3	–	Sell	-2,778	Closed	-$12K	–	2989
2022 Q2	$12K	Sell	2,778 -10,522	-79%	-$48K	﹤0.01%	2841
2022 Q1	$66K	Buy	+13,300	New	+$84.6K	﹤0.01%	2609

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RPCONE

Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

FLPIM

F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return

PFC

Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return

Russell Investments Group's ZVRA Position: Q2 2026 in Review

Russell Investments Group increased its Zevra Therapeutics (ZVRA) stake by 221% in Q2 2026, buying an estimated $125K and bringing the position to 16,395 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #3119.

Russell Investments Group first reported a position in ZVRA in Q1 2022 and has held it in 9 quarters since. 58 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Russell Investments Group held 16,395 shares of Zevra Therapeutics worth $235K as of Q2 2026.
Russell Investments Group bought 11,284 Zevra Therapeutics shares in Q2 2026, an estimated $125K.
Zevra Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3119 holding.
Russell Investments Group first reported a position in Zevra Therapeutics in Q1 2022 and has held it in 9 quarters since.
58 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.